share_log

Johnson & Johnson | 8-K: Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization

Johnson & Johnson | 8-K: Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization

強生 | 8-K:強生公司宣佈其子公司LLT Management LLC計劃通過雙方同意的 “預包裝” 重組解決所有當前和未來的卵巢癌滑石粉索賠
美股sec公告 ·  05/01 19:04
牛牛AI助理已提取核心訊息
On May 1, 2024, Johnson & Johnson released amended earnings for the first quarter ended March 31, 2024, reflecting a comprehensive Plan of Reorganization to settle ovarian cancer claims related to cosmetic talc litigation in the U.S. The plan excludes mesothelioma or State consumer protection claims and involves a payment of approximately $6.475 billion over 25 years. Due to this, the company recorded an additional charge of $2.7 billion, bringing the total reserve to a present value of about $11 billion. Consequently, GAAP net earnings for Q1 2024 were revised from $5.4 billion to $3.3 billion, and earnings per share (EPS) were adjusted from $2.20 to $1.34. The company's adjusted earnings, EPS, and operational EPS remain unaffected. The press release and financial statements detailing these changes were attached as exhibits to the SEC Form 8-K filing.
On May 1, 2024, Johnson & Johnson released amended earnings for the first quarter ended March 31, 2024, reflecting a comprehensive Plan of Reorganization to settle ovarian cancer claims related to cosmetic talc litigation in the U.S. The plan excludes mesothelioma or State consumer protection claims and involves a payment of approximately $6.475 billion over 25 years. Due to this, the company recorded an additional charge of $2.7 billion, bringing the total reserve to a present value of about $11 billion. Consequently, GAAP net earnings for Q1 2024 were revised from $5.4 billion to $3.3 billion, and earnings per share (EPS) were adjusted from $2.20 to $1.34. The company's adjusted earnings, EPS, and operational EPS remain unaffected. The press release and financial statements detailing these changes were attached as exhibits to the SEC Form 8-K filing.
2024年5月1日,強生公司發佈了截至2024年3月31日的第一季度修正業績,反映了一項全面的重組計劃,旨在解決與美國化妝品滑石粉訴訟相關的卵巢癌索賠。該計劃不包括間皮瘤或州消費者保護索賠,涉及在25年內支付約64.75億美元。因此,該公司記錄了27億美元的額外費用,使儲備金總額達到約110億美元的現值。因此,2024年第一季度的GAAP淨收益從54億美元修正爲33億美元,每股收益(EPS)從2.20美元調整爲1.34美元。該公司的調整後收益、每股收益和營業每股收益不受影響。詳細介紹這些變化的新聞稿和財務報表作爲證物附在SEC表格8-K文件中。
2024年5月1日,強生公司發佈了截至2024年3月31日的第一季度修正業績,反映了一項全面的重組計劃,旨在解決與美國化妝品滑石粉訴訟相關的卵巢癌索賠。該計劃不包括間皮瘤或州消費者保護索賠,涉及在25年內支付約64.75億美元。因此,該公司記錄了27億美元的額外費用,使儲備金總額達到約110億美元的現值。因此,2024年第一季度的GAAP淨收益從54億美元修正爲33億美元,每股收益(EPS)從2.20美元調整爲1.34美元。該公司的調整後收益、每股收益和營業每股收益不受影響。詳細介紹這些變化的新聞稿和財務報表作爲證物附在SEC表格8-K文件中。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。